Enterprise Value

-218M

Cash

456.8M

Avg Qtr Burn

-66.87M

Short % of Float

10.83%

Insider Ownership

1.34%

Institutional Own.

97.72%

Qtr Updated

03/31/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Dapirolizumab Pegol (anti-CD40L) Details
Systemic lupus erythematosus, Autoimmune disease

Phase 3

Data readout

Rezpegaldesleukin (NKTR-358) Details
Autoimmune disease, Atopic dermatitis

Phase 2b

Initiation

NKTR-255 + Avelumab Details
Urothelial carcinoma, Cancer

Phase 2

Data readout

NKTR-255 | IL-15R agonist + Cetuximab (Erbitux) | EGFR inhibitor Details
Colorectal cancer , Head and neck cancer, Head and neck squamous cell carcinoma, Cancer

Phase 1/2

Data readout

NKTR-255 | IL-15 agonist + Daratumumab Details
Non-Hodgkin lymphoma, Multiple myeloma, Cancer

Phase 1/2

Data readout

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Rezpegaldesleukin (LY3471851) (NKTR-358) Details
Autoimmune disease, Systemic lupus erythematosus

Failed

Discontinued

Bempegaldesleukin (NK-214) + VB10.NEO Details
Head and neck squamous cell carcinoma, Cancer

Failed

Discontinued

NKTR-358 Details
Autoimmune disease, Ulcerative colitis

Failed

Discontinued

Bempegaldesleukin (NKTR-214)+ OPDIVO (Nivolumab) Details
Urothelial cancer, Cancer, Bladder cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued

Onzeald (etirinotecan pegol) Details
Metastatic breast cancer to brain, Cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued